New imaging agent for breast cancer tested – but trial withdrawn
NCT ID NCT05634954
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-stage study aimed to test a new radioactive imaging agent called [18F]GEH121224 for detecting HER2-positive breast cancer using PET scans. The plan was to enroll 12 women with advanced breast cancer to check safety, radiation exposure, and the best timing for scans. However, the trial was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas MD Anderson Cancer Centre
Houston, Texas, 77030-4008, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]GEH121224 (a radioactive imaging agent for PET scans)
What this could lead to
If successful, this imaging agent could help doctors see HER2-positive breast cancer more clearly, guiding treatment decisions.
What could go wrong
This trial was withdrawn before any patients were enrolled, so no data is available. It is very early-stage research, and the agent may not prove safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.